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Promise for gene therapy in obstructive nephropathy
Obstructive nephropathy is a complex renal disor-
der that begins with hydrodynamic and hemodynamic
responses, leading to cellular changes in all renal com-
partments, and finally to interstitial fibrosis and tubular
atrophy. Over the past three decades, numerous phys-
iologic and molecular mechanisms that underlie these
observations have been elucidated. Much attention was
initially focused on renal vasoconstriction resulting from
ureteral obstruction, and subsequent studies revealed a
role for angiotensin II, thromboxanes, and endothelin [1].
As with most regulatory processes, counteracting forces
(in the form of vasodilators) have been shown to mod-
ulate the effects of endogenous vasoconstrictors in the
hydronephrotic kidney. In 1992, we reported that endoge-
nous endothelial-relaxing factor (now identified as ni-
tric oxide) attenuates the vasoconstriction resulting from
acute unilateral ureteral obstruction (UUO) in the rat
[2]. In a recent report, arginine infusion was shown to
increase glomerular filtration rate (GFR) of both ob-
structed and contralateral kidneys, which is accompanied
by an increase in renal inducible NOS (iNOS) activity
[3]. Either angiotensin inhibition or stimulation of en-
dogenous NOS with arginine could increase renal NOS
activity, which appears to suppress macrophage infiltra-
tion, myofibroblast transformation, and progression of
interstitial fibrosis following UUO [4]. Subsequent stud-
ies showed that targeted disruption of iNOS aggravates
transforming growth factor-b1 (TGF-b1) expression and
macrophage accumulation following UUO in mice [5].
These observations underscore the cellular role of nitric
oxide in the hydronephrotic kidney, with evidence for
both anti-inflammatory and antifibrotic effects.
Recently, arginine infusions in dogs with 18 hours of
UUO were shown to increase renal blood flow, leading
to the conclusion that a lack of substrate may contribute
to the profound vasoconstriction resulting from chronic
UUO [6]. Chronic UUO in mice leads to a progressive re-
duction in the production of iNOS by the obstructed kid-
ney, and tubular apoptosis is even more severe following
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UUO in mice lacking the gene for iNOS [7]. Mechanical
stretch of tubular epithelial cells due to tubular dilatation
appears to be a major factor contributing to apoptosis
following UUO, and axial strain on cultured tubular cells
increases iNOS expression [8]. Moreover, inhibition of
endogenous iNOS increases stretch-induced apoptosis in
rat renal tubular cells [7].
Experimental manipulation of processes responsi-
ble for the initiation and progression of obstructive
nephropathy has involved a number of techniques, in-
cluding the administration of growth factors, inhibitors,
and antisense oligonucleotides. Since most clinical ob-
structive nephropathy is a chronic process, there is con-
siderable interest in developing long-term treatment
options, such as gene therapy. Hepatocyte growth fac-
tor (HGF), which has antifibrotic actions in the hy-
dronephrotic kidney [9], is an attractive candidate for
gene therapy. The transduction of skeletal muscle with
the HGF gene using liposomes containing the hemag-
glutinating virus of Japan has been shown to suppress
macrophage infiltration, tubular apoptosis, interstitial fi-
brosis, and tubular atrophy following chronic UUO in the
rat [9]. A second report of HGF gene transfer by intra-
venous injection of plasmid vector into mice with chronic
UUO demonstrates a synergistic protective effect in com-
bination with angiotensin II blockade [10]. The salutary
effects include a reduction in myofibroblast transforma-
tion, decreased TGF-b1 expression, and preservation of
renal mass [10].
In this issue of Kidney International, Ito et al demon-
strate improved renal function by intraureteral adminis-
tration of the iNOS gene in rats with 24 hours’ UUO [11].
The intramuscular route of administration was not used
because myocyte expression of intracellular proteins such
as iNOS would not likely affect the kidney. In this very
well controlled study using cationic liposomes as the vehi-
cle, iNOS was localized to collecting ducts, distal tubules,
and glomeruli. Importantly, renal expression of iNOS
and urinary NO2/NO3 remained elevated more than
30 days after transfection (previous reports of kidney-
targeted viral-mediated delivery of genes have not shown
long-term expression) [11]. While iNOS transduction was
performed seven days prior to ureteral obstruction, and
functional studies were performed after only 24 hours of
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UUO, the authors indicate that longer term studies of
morphologic effects of iNOS transduction are to follow.
Of note, iNOS gene expression was increased also in the
contralateral kidney, and some glomerular expression of
the transfected iNOS appeared in glomeruli of the in-
tact contralateral kidney. Despite this, the lack of effect
of transfected iNOS on renal function in nonoperated
control animals suggests that a physiologic response is
elicited only in the pathologic kidney.
This is a promising study, indicating that liposome-
mediated intraureteral transfer of the iNOS gene can
have significant salutary effects in a model of obstruc-
tive nephropathy. The information gained by augmen-
tation of iNOS gene expression complements studies of
UUO in iNOS knockout mice. However, many hurdles
remain before this approach becomes a potential ther-
apeutic modality. The cellular and physiologic roles of
nitric oxide in the hydronephrotic kidney are highly com-
plex. For example, whether nitric oxide acts as an anti-
apoptotic or a proapoptotic modulator may depend on its
local concentration, which can be difficult to regulate with
intraureteral injection of the transfected liposome [12]. In
addition, nitric oxide appears to mediate the stimulation
of TGF-b1 by angiotensin II (a fibrogenic pathway), and
TGF-b1, in turn, inhibits iNOS [8]. For optimal therapeu-
tic efficacy, the iNOS gene may need to be delivered to
specific intrarenal compartments or cell types, and during
defined intervals. More answers are certain to be forth-
coming from this productive laboratory that has taught us
much about the intricacies of nitric oxide in obstructive
nephropathy.
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